Latest Period
Q2 2026
Security Snapshot
Lakefront Biotherapeutics NV - Ordinary shares, no nominal value per share (the "Ordinary Shares") (LKFT) Institutional Ownership
CUSIP: 36315X101
13F Institutional Holders and Ownership History from Q2 2015 to Q2 2026
Institutions Reporting
77
Shares (Excl. Options)
32,057,075
Price
$29.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary shares, no nominal value per share (the "Ordinary Shares")
- Symbol
- LKFT on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 32,057,075
- Total 13F value
- $960,330,510
- Portfolio coverage rank
- 0%
- Share change
- +798,725
- Value change
- +$23,929,787
- Number of holders
- 77
- Shares outstanding
- 65,567,327
- SEC-reported price per share
- $28.15
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LKFT - Lakefront Biotherapeutics NV - Ordinary shares, no nominal value per share (the "Ordinary Shares") is tracked under CUSIP 36315X101.
- 77 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 90 to 77 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $937,850,803 to $960,330,510.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 77 institutions filings for Q2 2026.
Security key
36315X101
Latest holder period
Q2 2026
13F holders
77
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
LKFT full holder history
Lakefront Biotherapeutics NV SEC filings
Lakefront Biotherapeutics NV company facts
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 36315X101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
LKFT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 30% | $555,786,955 | 20,981,010 | Gilead Sciences, Inc. | 07 Jan 2025 | |||
| EcoR1 Capital, LLC | 13% | +12% | $243,919,471 | +$25,507,847 | 8,714,522 | +12% | EcoR1 Capital, LLC | 24 Jul 2025 |
| TANG CAPITAL MANAGEMENT LLC | 8.4% | +11% | $192,587,107 | +$22,486,521 | 5,559,674 | +13% | TANG CAPITAL MANAGEMENT, LLC | 27 Oct 2025 |
| Madison Avenue Partners, LP | 5.5% | $95,961,062 | 3,606,203 | Madison Avenue International LP | 15 Jun 2026 |
As of 30 Jun 2026, 77 institutional investors reported holding 32,057,075 shares of Lakefront Biotherapeutics NV - Ordinary shares, no nominal value per share (the "Ordinary Shares") (LKFT). This represents 49% of the company’s total 65,567,327 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
49%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 25% | 16,707,477 | 0% | 30% | $500,157,715 |
| TANG CAPITAL MANAGEMENT LLC | 5.8% | 3,785,991 | 0% | 5.2% | $113,504,010 |
| Madison Avenue Partners, LP | 5.3% | 3,447,807 | +40% | 4.4% | $103,365,254 |
| Prosight Management, LP | 3.1% | 2,043,344 | +32% | 11% | $61,259,453 |
| EcoR1 Capital, LLC | 2.5% | 1,667,119 | 0% | 2.5% | $49,980,228 |
| AMERIPRISE FINANCIAL INC | 1.9% | 1,272,249 | -11% | 0.01% | $38,140,727 |
| DME Capital Management, LP | 0.74% | 482,746 | 0% | 0.37% | $14,472,725 |
| RENAISSANCE TECHNOLOGIES LLC | 0.62% | 407,800 | +29% | 0.02% | $12,225,844 |
| BlackRock, Inc. | 0.52% | 338,152 | +8.3% | 0% | $10,137,797 |
| Point72 Asset Management, L.P. | 0.41% | 269,814 | -19% | 0.01% | $8,089,024 |
| D. E. Shaw & Co., Inc. | 0.3% | 197,844 | -8.3% | 0% | $5,931,363 |
| MILLENNIUM MANAGEMENT LLC | 0.28% | 181,090 | +68% | 0% | $5,429,078 |
| UBS Group AG | 0.26% | 168,148 | -4.1% | 0% | $5,041,077 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.23% | 151,886 | +1035% | 0% | $4,553,542 |
| DAFNA Capital Management LLC | 0.2% | 130,175 | 0% | 0.74% | $3,902,647 |
| CITADEL ADVISORS LLC | 0.13% | 88,343 | -29% | 0% | $2,648,524 |
| TWO SIGMA INVESTMENTS, LP | 0.12% | 81,749 | +216% | 0% | $2,450,835 |
| NORGES BANK | 0.12% | 76,879 | 0% | $2,304,832 | |
| ALPS ADVISORS INC | 0.1% | 65,523 | +22% | 0.01% | $1,964,380 |
| GOLDMAN SACHS GROUP INC | 0.09% | 56,581 | +25% | 0% | $1,696,298 |
| AMERICAN CENTURY COMPANIES INC | 0.06% | 40,804 | +5.2% | 0% | $1,223,304 |
| BAROMETER CAPITAL MANAGEMENT INC. | 0.06% | 40,800 | +7.1% | 0.34% | $1,223,184 |
| MORGAN STANLEY | 0.06% | 37,682 | +42% | 0% | $1,129,706 |
| Schonfeld Strategic Advisors LLC | 0.05% | 32,597 | 0.01% | $977,256 | |
| MARSHALL WACE, LLP | 0.05% | 32,399 | 0% | $971,321 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
45
Latest
Q2 2026
Rows shown
1-25 of 45
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 32,057,075 | $960,330,510 | +$23,929,787 | $29.98 | 77 |
| 2026 Q1 | 31,262,417 | $937,850,803 | -$1,948,311 | $30.00 | 90 |
| 2025 Q4 | 31,396,165 | $1,030,612,133 | -$423,032 | $32.70 | 92 |
| 2025 Q3 | 31,401,256 | $1,087,732,117 | -$7,956,750 | $34.64 | 92 |
| 2025 Q2 | 31,697,765 | $887,221,465 | +$28,214,019 | $27.99 | 85 |
| 2025 Q1 | 31,070,295 | $780,194,528 | -$4,334,186 | $25.12 | 82 |
| 2024 Q4 | 31,079,138 | $856,919,857 | +$17,773,347 | $27.50 | 81 |
| 2024 Q3 | 13,663,353 | $393,374,763 | -$177,023,110 | $28.79 | 77 |
| 2024 Q2 | 19,935,693 | $494,012,131 | -$14,463,813 | $24.78 | 82 |
| 2024 Q1 | 20,486,366 | $659,634,802 | +$21,269,889 | $32.20 | 79 |
| 2023 Q4 | 19,790,623 | $804,487,651 | +$20,616,236 | $40.65 | 87 |
| 2023 Q3 | 19,171,399 | $662,382,310 | -$16,486,115 | $34.55 | 72 |
| 2023 Q2 | 19,708,613 | $801,351,937 | +$60,840,835 | $40.66 | 73 |
| 2023 Q1 | 18,215,508 | $703,834,822 | +$192,041,792 | $38.64 | 72 |
| 2022 Q4 | 13,177,559 | $584,821,554 | +$12,983,412 | $44.38 | 71 |
| 2022 Q3 | 12,911,798 | $550,549,123 | -$12,978,528 | $42.64 | 77 |
| 2022 Q2 | 12,900,644 | $719,839,590 | -$9,312,560 | $55.80 | 79 |
| 2022 Q1 | 12,830,797 | $795,810,983 | +$134,250,057 | $62.02 | 86 |
| 2021 Q4 | 10,793,402 | $595,046,185 | +$111,349,568 | $55.13 | 81 |
| 2021 Q3 | 8,551,124 | $449,836,824 | +$478,944 | $52.61 | 80 |
| 2021 Q2 | 7,506,771 | $517,197,342 | +$62,993,693 | $68.89 | 99 |
| 2021 Q1 | 6,565,519 | $505,977,352 | +$131,911,497 | $77.09 | 123 |
| 2020 Q4 | 4,564,667 | $452,130,046 | -$397,947,991 | $98.98 | 106 |
| 2020 Q3 | 7,422,842 | $1,053,286,217 | -$44,029,693 | $141.91 | 116 |
| 2020 Q2 | 7,628,171 | $1,504,806,578 | -$6,418,127 | $197.29 | 138 |